Washington settles generic drug cases with Ascend Laboratories, Citron Pharma, and Mayne Pharma

Washington settles generic drug cases with Ascend Laboratories, Citron Pharma, and Mayne Pharma FOR IMMEDIATE RELEASE: Oct 14 2026 atgAshleyGross Wed, 10/14/2026 - 13:53 Washington, as part of a bipartisan coalition of 45 states and territories, has reached settlements with Ascend Laboratories, Citron Pharma and Mayne Pharma to resolve allegations the generic drug manufacturers engaged in a long-running conspiracy to artificially inflate and manipulate prices and reduce competition. Ascend will pay $400,000 to the states. Mayne will pay $650,000. Citron’s settlement only includes non-monetary terms as it has ceased business operations. As part of the settlement, the companies each agreed to change their practices to ensure fair competition and compliance with antitrust laws. The coalition of nearly all states and territories, led by Connecticut, is engaged in a series of antitrust cases involving generic drug manufacturers, starting first in 2016. The trial scheduled for February in Hartford, Conn., focuses on the states’ dermatology case. In their complaint, the states allege that 26 corporate defendants and 10 individual defendants conspired to fix prices and allocate markets on

Résiliable à tout moment · 99 $ CA/mois